Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?
Genmab A/S (GMAB) shares rose after TheFly reported H.C. Wainwright raised its GMAB price target to $40 from $38 and kept a Buy rating following positive EPCORE DLBCL-4 trial results for Epkinly. Genmab also said the European Commission approved TEPKINLY with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, based on Phase 3 EPCORE FL-1.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the European Commission’s marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, supported by Phase 3 EPCORE FL-1 data.
Market read
Regulatory approval reduces approval risk and can improve commercial expectations for Genmab’s oncology pipeline, supporting bullish positioning around the approval milestone.
What to watch
Traders may need to monitor confirmatory post-approval requirements, real-world durability versus trial endpoints, and how combination uptake compares with existing R2-based standards.
Background
The article frames Genmab’s Epkinly/TEPKINLY franchise around EPCORE DLBCL-4 and EPCORE FL-1 Phase 3 trial outcomes, plus an analyst price-target increase tied to regulatory likelihood assumptions.
Ticker impact
Genmab said the European Commission approved TEPKINLY plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, citing EPCORE FL-1 Phase 3 results.
Near-term upside bias as traders price in reduced regulatory uncertainty and potential uptake in relapsed/refractory follicular lymphoma.
The article discloses a specific regulator action (EC approval) tied to Phase 3 data, which is typically material for biotech revenue expectations and sentiment. However, it does not provide revenue estimates, launch timing, or guidance, limiting precision.
Market effects
Reinforces demand for fixed-duration, chemotherapy-free or chemo-sparing regimens in relapsed follicular lymphoma, potentially supporting sentiment for similar oncology antibody programs.
EU approval can shift expectations for European commercial adoption and payer discussions for relapsed/refractory follicular lymphoma therapies.
US/Japan commercialization is shared with AbbVie per the article, so EU approval can improve global partner confidence and execution expectations.
Counterpoint
Regulatory approval is positive, but the article provides no sales ramp details, pricing, or competitive positioning, so the market may already be discounting the approval narrative.
Key entities
- companyGenmab A/S
Subject of the article; received European Commission marketing authorization for TEPKINLY combination therapy in relapsed/refractory follicular lymphoma.
- regulatorEuropean Commission
Approved marketing authorization for TEPKINLY plus lenalidomide and rituximab based on EPCORE FL-1 Phase 3 results.
- companyAbbVie
Oncology partnership with Genmab; shares commercial responsibilities in the U.S. and Japan per the article.
